Abstract
There are several microRNAs that have been consistently reported to be differentially expressed in esophageal squamous cell carcinoma vs. normal squamous tissue, with prognostic associations for miR-21 (invasion, positive nodes, decreased survival), miR-143 (disease recurrence, invasion depth), and miR-375 (inversely correlated with advanced stage, distant metastasis, poor overall survival, and disease-free survival). There is also evidence that miR-375 regulates gene expression associated with resistance to chemotherapy. Hence, microRNA expression assays have the potential to provide clinically relevant information about prognosis and potential response to chemotherapy in patients with esophageal squamous cell carcinoma. Results are inconsistent, however, for microRNAs across different studies for esophageal adenocarcinoma (EAC) vs. its precursor lesion Barrett’s esophagus. These inconsistencies may partly result from pathological and/or molecular heterogeneity in both Barrett’s esophagus and EAC, but may also result from differences in study designs or different choices of comparator tissues. Despite these inconsistencies, however, several mRNA/protein targets have been identified, the cancer related biology of some of these targets is well understood, and there are clinico-pathological associations for some of these mRNA targets. MicroRNAs also have potential for use in therapy for esophageal cancers. The development of new delivery methods, such as minicells and autologous microvesicles, and molecular modifications such as the addition of aromatic benzene pyridine analogs, have facilitated the exploration of the effects of therapeutic microRNAs in vivo. These approaches are producing encouraging results, with one technology in a phase I/IIa clinical trial.
Keywords: microRNA, esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, miR-21, miR-143, miR-375, Barrett’s esophagus, mRNA targets, clinical trial
Current Pharmaceutical Design
Title:microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Volume: 19 Issue: 7
Author(s): George C. Mayne, Damian J. Hussey and David I. Watson
Affiliation:
Keywords: microRNA, esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, miR-21, miR-143, miR-375, Barrett’s esophagus, mRNA targets, clinical trial
Abstract: There are several microRNAs that have been consistently reported to be differentially expressed in esophageal squamous cell carcinoma vs. normal squamous tissue, with prognostic associations for miR-21 (invasion, positive nodes, decreased survival), miR-143 (disease recurrence, invasion depth), and miR-375 (inversely correlated with advanced stage, distant metastasis, poor overall survival, and disease-free survival). There is also evidence that miR-375 regulates gene expression associated with resistance to chemotherapy. Hence, microRNA expression assays have the potential to provide clinically relevant information about prognosis and potential response to chemotherapy in patients with esophageal squamous cell carcinoma. Results are inconsistent, however, for microRNAs across different studies for esophageal adenocarcinoma (EAC) vs. its precursor lesion Barrett’s esophagus. These inconsistencies may partly result from pathological and/or molecular heterogeneity in both Barrett’s esophagus and EAC, but may also result from differences in study designs or different choices of comparator tissues. Despite these inconsistencies, however, several mRNA/protein targets have been identified, the cancer related biology of some of these targets is well understood, and there are clinico-pathological associations for some of these mRNA targets. MicroRNAs also have potential for use in therapy for esophageal cancers. The development of new delivery methods, such as minicells and autologous microvesicles, and molecular modifications such as the addition of aromatic benzene pyridine analogs, have facilitated the exploration of the effects of therapeutic microRNAs in vivo. These approaches are producing encouraging results, with one technology in a phase I/IIa clinical trial.
Export Options
About this article
Cite this article as:
C. Mayne George, J. Hussey Damian and I. Watson David, microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy, Current Pharmaceutical Design 2013; 19 (7) . https://dx.doi.org/10.2174/138161213804805702
DOI https://dx.doi.org/10.2174/138161213804805702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50
Letters in Drug Design & Discovery Mammalian Cell Competitions, Cell-in-Cell Phenomena and Their Biomedical Implications.
Current Molecular Medicine Flavonoids Influence Epigenetic-Modifying Enzyme Activity: Structure-Function Relationships and the Therapeutic Potential for Cancer
Current Medicinal Chemistry The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Current Medicinal Chemistry Radiation-Induced Oral Mucositis in Head and Neck Cancer Patients. Five Years Literature Review
Reviews on Recent Clinical Trials Advances in Human Cytochrome P450 and Personalized Medicine
Current Drug Metabolism Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Current Medicinal Chemistry KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker
Combinatorial Chemistry & High Throughput Screening The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression
Current Drug Targets Treat to Target for Osteoporosis: Another Step Forward
Current Rheumatology Reviews Trends in Malignant Glioma Monoclonal Antibody Therapy
Current Cancer Therapy Reviews VEGFA and PlGF Protein Signature of Primary Stage IV Rectal Cancer Pre and Post Neoadjuvant Radiotherapy, Bevacizumab, and Chemotherapy
Current Angiogenesis (Discontinued) RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry